Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder

被引:12
|
作者
Lees, Rachel [1 ]
Hines, Lindsey A. A. [3 ]
Hindocha, Chandni [4 ]
Baio, Gianluca [5 ]
Shaban, Natacha D. C. [6 ]
Stothart, George [2 ]
Mofeez, Ali [7 ]
Morgan, Celia J. A. [8 ]
Curran, H. Valerie [4 ]
Freeman, Tom P. P. [1 ]
机构
[1] Univ Bath, Dept Psychol, Addict & Mental Hlth Grp, Bath, England
[2] Univ Bath, Dept Psychol, Bath, England
[3] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, England
[4] UCL, Clin Psychopharmacol Unit, London, England
[5] UCL, Dept Stat Sci, London, England
[6] Univ Oxford, Oxford, England
[7] UCLH, Natl Hosp Neurol & Neurosurg, Pain Management Ctr, London, England
[8] Univ Exeter, Psychopharmacol & Addict Res Ctr, Exeter, England
基金
英国医学研究理事会;
关键词
Cannabidiol; Cannabis use disorder; Clinical trial; Cognition; Verbal learning and memory; MEMORY; SYMPTOMS; INTERVENTION; CBD;
D O I
10.1007/s00213-022-06303-5
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale:Chronic cannabis use is associated with impaired cognitive function. Evidence indicates cannabidiol (CBD) might be beneficial for treating cannabis use disorder. CBD may also have pro-cognitive effects; however, its effect on cognition in people with cannabis use disorder is currently unclear. Objectives:We aimed to assess whether a 4-week CBD treatment impacted cognitive function. We hypothesised that CBD treatment would improve cognition from baseline to week 4, compared to placebo. Methods:Cognition was assessed as a secondary outcome in a phase 2a randomised, double-blind, parallel-group and placebo-controlled clinical trial of 4-week daily 200 mg, 400 mg and 800 mg CBD for the treatment of cannabis use disorder. Participants had moderate or severe DSM-5 cannabis use disorder and intended to quit cannabis use. Our pre-registered primary cognitive outcome was delayed prose recall. Secondary cognitive outcomes were immediate prose recall, stop signal reaction time, trail-making task performance, verbal fluency and digit span. Results:Seventy participants were randomly assigned to placebo (n = 23), 400 mg CBD (n = 24) and 800 mg CBD (n = 23). A 200 mg group was eliminated from the trial because it was an inefficacious dose at interim analysis (n = 12) and was not analysed here. For the primary cognitive outcome, there was no effect of CBD compared to placebo, evidenced by a lack of dose-by-time interaction at 400 mg (0.46, 95%CIs: - 1.41, 2.54) and 800 mg (0.89, 95%CIs: - 0.99, 2.81). There was no effect of CBD compared to placebo on secondary cognitive outcomes, except backwards digit span which increased following 800 mg CBD (0.30, 95%CIs: 0.02, 0.58). Conclusions:In this clinical trial for cannabis use disorder, CBD did not influence delayed verbal memory. CBD did not have broad cognitive effects but 800 mg daily treatment may improve working memory manipulation.
引用
收藏
页码:337 / 346
页数:10
相关论文
共 37 条
  • [1] Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder
    Rachel Lees
    Lindsey A. Hines
    Chandni Hindocha
    Gianluca Baio
    Natacha D. C. Shaban
    George Stothart
    Ali Mofeez
    Celia J. A. Morgan
    H. Valerie Curran
    Tom P. Freeman
    Psychopharmacology, 2023, 240 : 337 - 346
  • [2] Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: findings from a randomised clinical trial for the treatment of cannabis use disorder
    Hua, Daniel Ying-Heng
    Hindocha, Chandni
    Baio, Gianluca
    Lees, Rachel
    Shaban, Natacha
    Morgan, Celia J. J.
    Mofeez, Ali
    Curran, H. Valerie
    Freeman, Tom P. P.
    TRANSLATIONAL PSYCHIATRY, 2023, 13 (01)
  • [3] A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol
    Bhardwaj, Anjali K.
    Mills, Llew
    Doyle, Michael
    Sahid, Arshman
    Montebello, Mark
    Monds, Lauren
    Arunogiri, Shalini
    Haber, Paul
    Lorenzetti, Valentina
    Lubman, Dan I.
    Malouf, Peter
    Harrod, Mary E.
    Dunlop, Adrian
    Freeman, Tom
    Lintzeris, Nicholas
    BMC PSYCHIATRY, 2024, 24 (01)
  • [4] Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder
    Llewellyn Mills
    Adrian Dunlop
    Mark Montebello
    Jan Copeland
    Raimondo Bruno
    Meryem Jefferies
    Iain Mcgregor
    Nicholas Lintzeris
    Substance Abuse Treatment, Prevention, and Policy, 17
  • [5] Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder
    Mills, Llewellyn
    Dunlop, Adrian
    Montebello, Mark
    Copeland, Jan
    Bruno, Raimondo
    Jefferies, Meryem
    Mcgregor, Iain
    Lintzeris, Nicholas
    SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY, 2022, 17 (01)
  • [6] A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol
    Anjali K. Bhardwaj
    Llew Mills
    Michael Doyle
    Arshman Sahid
    Mark Montebello
    Lauren Monds
    Shalini Arunogiri
    Paul Haber
    Valentina Lorenzetti
    Dan I. Lubman
    Peter Malouf
    Mary E. Harrod
    Adrian Dunlop
    Tom Freeman
    Nicholas Lintzeris
    BMC Psychiatry, 24
  • [7] Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial
    Solowij, Nadia
    Broyd, Samantha J.
    Beale, Camilla
    Prick, Julie-Anne
    Greenwood, Lisa-marie
    van Hell, Hendrika
    Suo, Chao
    Galettis, Peter
    Pai, Nagesh
    Fu, Shanlin
    Croft, Rodney J.
    Martin, Jennifer H.
    Yuecel, Murat
    CANNABIS AND CANNABINOID RESEARCH, 2018, 3 (01) : 21 - 34
  • [8] Matching adolescents with a cannabis use disorder to multidimensional family therapy or cognitive behavioral therapy: Treatment effect moderators in a randomized controlled trial
    Hendriks, Vincent
    van der Schee, Evelien
    Blanken, Peter
    DRUG AND ALCOHOL DEPENDENCE, 2012, 125 (1-2) : 119 - 126
  • [9] The Influence of Personality Disorder Symptoms on Treatment Outcomes in Bipolar Disorder: A Secondary Analysis of a Randomised Controlled Trial
    Sarmiento, Alessandra
    Dean, Olivia M.
    Kavanagh, Bianca E.
    Mohebbi, Mohammadreza
    Berk, Michael
    Dodd, Seetal
    Cotton, Sue M.
    Malhi, Gin S.
    Ng, Chee H.
    Turner, Alyna
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2024, 69 (04): : 275 - 287
  • [10] Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial
    Rasmussen, Jesper Ostrup
    Jennum, Poul
    Linnet, Kristian
    Glenthoj, Birte Y.
    Baandrup, Lone
    BMC PSYCHIATRY, 2021, 21 (01)